Evergen

Evergen operates as a specialized CDMO in the regenerative medicine space, leveraging a patient-first partnership model with OEMs. It provides end-to-end services from biomaterial development to commercial manufacturing, utilizing a portfolio of processed human and animal tissues. With a track record of over 20 million implants and hundreds of regulatory clearances, the company is positioned as an established service provider in a high-growth therapeutic area. Its leadership team brings decades of industry experience from major healthcare companies, focusing on quality, innovation, and clinical expertise.

A tissue engineering and processing platform focused on customizing allograft (human) and xenograft (animal) biomaterials through specialized material and process technologies (e.g., decellularization, sterilization, forming) to create regenerative implants for surgical applications.

Evergen competes in the regenerative medicine CDMO space against larger, diversified CDMOs (e.g., Lonza, Catalent) and smaller specialized tissue processors. Its differentiation lies in its deep, focused expertise in processed biologic implants for specific surgical applications and its end-to-end service model from development to commercial manufacturing.